ZNTL · Company research
Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals (ZNTL) Shares Rise After Positive Mid-Stage Trial Data for Azenosertib - GuruFocus | Zentalis Pharmaceuticals (ZNTL) Shares Rise After Positive Mid-Stage Trial Data for Azenosertib GuruFocus | View source ↗ | GuruFocus | Oct 19, 2026 | neutral | 0 | 0.6 |
| Zentalis stock rises on cancer trial data (ZNTL:NASDAQ) - Seeking Alpha | Zentalis stock rises on cancer trial data (ZNTL:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 19, 2026 | neutral | 0 | 0.6 |
| Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract | Zentalis Pharmaceuticals announced interim overall survival data from the DENALI Part 1b study of azenosertib, its investigational WEE1 inhibitor for platinum-resistant ovarian cancer. In Cyclin E1-positive patients (n=48), median OS was 15.8 months compared to 7.5 months in Cyclin E1-negative patients (n=46). The company concluded that Cyclin E1 is a highly selective biomarker for azenosertib response, with OS data comparing favorably to historical chemotherapy benchmarks, supporting continued development in Phase 3 trials. | View source ↗ | GlobeNewswire Inc. | Oct 18, 2026 | bullish | 1 | 1 |
| ZNTL Stock Price, Quote & News - Syfe | ZNTL Stock Price, Quote & News Syfe | View source ↗ | Syfe | Oct 15, 2026 | neutral | 0 | 0.6 |
| ZNTL - Late Stage Ovarian Cancer Trials And Extended Cash Runway Will Support Future Upside Potential - Simply Wall Street | ZNTL - Late Stage Ovarian Cancer Trials And Extended Cash Runway Will Support Future Upside Potential Simply Wall Street | View source ↗ | Simply Wall Street | Oct 7, 2026 | neutral | 0 | 0.6 |
| At $2.18 a share, Ingmar Bruns acquires 9,727 shares in Zentalis Pharmaceuticals (ZNTL). - Stock Titan | At $2.18 a share, Ingmar Bruns acquires 9,727 shares in Zentalis Pharmaceuticals (ZNTL). Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Zentalis raises $92.6M for trials, filings and what follows - Stock Titan | Zentalis raises $92.6M for trials, filings and what follows Stock Titan | View source ↗ | Stock Titan | Aug 17, 2026 | neutral | 0 | 0.6 |
| Stocks to watch on Thursday after hours: AMAT, DLO, ZNTL (AMAT:NASDAQ) - Seeking Alpha | Stocks to watch on Thursday after hours: AMAT, DLO, ZNTL (AMAT:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 13, 2026 | neutral | 0 | 0.6 |
| Zentalis Pharmaceuticals stock falls on public offering news - Investing.com | Zentalis Pharmaceuticals stock falls on public offering news Investing.com | View source ↗ | Investing.com | Aug 13, 2026 | neutral | 0 | 0.6 |
| $ZNTL stock is down 15% today. Here's what we see in our data. - Quiver Quantitative | $ZNTL stock is down 15% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 7, 2026 | neutral | 0 | 0.6 |
| ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? - Yahoo Finance | ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 20, 2026 | neutral | 0 | 0.6 |
| Should I buy Zentalis Pharmaceuticals (ZNTL) - Zacks Investment Research | Should I buy Zentalis Pharmaceuticals (ZNTL) Zacks Investment Research | View source ↗ | Zacks Investment Research | Jul 20, 2026 | neutral | 0 | 0.6 |
| A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Yahoo Finance | A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone Yahoo Finance | View source ↗ | Yahoo Finance | Apr 12, 2026 | neutral | 0 | 0.6 |
| Is Zentalis (ZNTL) Using Azenosertib’s New Dose To Reframe Its Ovarian Cancer Strategy? - Simply Wall Street | Is Zentalis (ZNTL) Using Azenosertib’s New Dose To Reframe Its Ovarian Cancer Strategy? Simply Wall Street | View source ↗ | Simply Wall Street | Apr 11, 2026 | neutral | 0 | 0.6 |
| ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update - Stocktwits | ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update Stocktwits | View source ↗ | Stocktwits | Apr 10, 2026 | neutral | 0 | 0.6 |
| $ZNTL stock is up 14% today. Here's what we see in our data. - Quiver Quantitative | $ZNTL stock is up 14% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 9, 2026 | neutral | 0 | 0.6 |
| ZNTL Should I Buy - Intellectia AI | ZNTL Should I Buy Intellectia AI | View source ↗ | Intellectia AI | Apr 4, 2026 | neutral | 0 | 0.6 |
| Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) Stock Price: Oct 8 Close $2.51 - Gotrade | Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) Stock Price: Oct 8 Close $2.51 Gotrade | View source ↗ | Gotrade | Jan 13, 2026 | neutral | 0 | 0.6 |
| Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m - Investing.com | Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m Investing.com | View source ↗ | Investing.com | Jan 8, 2026 | neutral | 0 | 0.6 |
| Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis - Stock Titan | Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis Stock Titan | View source ↗ | Stock Titan | Apr 25, 2025 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Feb 12, 2024 | neutral | 0 | 0.6 |
| Zentalis Pharmaceuticals (Nasdaq:ZNTL) - Stock Analysis - Simply Wall Street | Zentalis Pharmaceuticals (Nasdaq:ZNTL) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Apr 11, 2020 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.